Cancer ResearchFDA Approves Zenocutuzumab-zbco for Advanced Cholangiocarcinoma
The FDA approved zenocutuzumab-zbco on May 8, 2026, for adults with advanced, unresectable, or metastatic cholangiocarcinoma — a rare and aggressive cancer of the bile ducts. Cholangiocarcinoma is notoriously difficult to treat, with limited effective options once it reaches advanced stages, making new approvals clinically significant. The source reviewed (FDA oncology approval notifications) confirms the approval and indication but does not provide mechanistic details, trial data, or biomarker requirements in the excerpt available. Clinicians should consult full FDA prescribing information for eligibility criteria, dosing, and safety data before use.
